Concepedia

James H. Revkin

JH

Statistics

Publications

22

Citations

7K

H-Index

17

Active since

1987

Affiliations

Pfizer (United States)(Current)

Amsterdam UMC Location University of Amsterdam

University of Amsterdam

Montreal Heart Institute

Harvard University

James H. Revkin is an author at Pfizer (United States) specializing in pharmacology, cardiovascular pharmacotherapy, and medicine.

ORCID

Publications per year

1987–2024

22

Publications

22

Effects of Torcetrapib in Patients at High Risk for Coronary Events

Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

, , +14

Effect of Torcetrapib on the Progression of Coronary Atherosclerosis

Steven E. Nissen, Jean‐Claude Tardif, Stephen J. Nicholls et al. · New England Journal of Medicine · 2007 · 965 citations · Full text

, , +12

Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

John J.P. Kastelein, Sander I. van Leuven, Leslie Burgess et al. · New England Journal of Medicine · 2007 · 665 citations

, , +17

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Paul M. Ridker, James H. Revkin, Pierre Amarenco et al. · New England Journal of Medicine · 2017 · 630 citations · Full text

, , +17

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Michiel L. Bots, Frank L.J. Visseren, Gregory W. Evans et al. · The Lancet · 2007 · 458 citations

, , +8

1–5 of 22